Bioequivalence and Bioavailability Forum 00:23 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

bjkim97
Junior

Korea / Seoul,
2018-05-30 08:41

Posting: # 18828
Views: 675
 

 How to demonstrate the bioequivalence of sulodexide [Design Issues]

We are planning to development of the sulodexide.

As far as I Know, this product does not have accurate guldelines and design.

So I have reviewed several documents. The FDA and EMEA have identified guidelines for LMWH.

The sulodexide is defined as follows.

Sulodexide is highly purifuled mixture of glycosaminoglycans composed of FMH (Fast Moving Heparin) (80%) and Dermatan sulfate (20%).

I will refer to the FDA enoxaparin recommend guidelines for pharmacodynamic equivalence.

Just one question:
I am not sure if enoxaparin recommendations can be applied to Sulodexide.

I want to hear your opinion. Please give me your opinion

Thanks.

BJ
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,923 posts in 4,039 threads, 1,284 registered users;
online 5 (0 registered, 5 guests [including 5 identified bots]).

If you think it’s simple,
then you have misunderstood the problem.    Bjarne Stroustrup

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed